GRI Bio reports Q3 net loss $11M; cash $3.5M; IPF trial on track

GRI Bio, Inc.

2023-Q3 EPS reported -$3.83

Net loss $11.0M for 9 months ended Sep 30, 2023; R&D expenses $2.2M (vs $0.2M YoY) and G&A $7.2M (vs $0.4M YoY).
Cash and equivalents $3.5M as of Sep 30, 2023.
Phase 2a biomarker study of GRI-0621 for IPF on track to start before year-end 2023; interim data expected H1 2024.
GRI-0803 SLE program on track for IND filing H1 2024; Phase 1a SAD topline data expected Q3 2024.
Entered asset purchase agreement with Aardvark Therapeutics to sell legacy ADAIR assets and IP (no financial terms disclosed).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GRI Bio, Inc. reported the quarter ended September 30, 2023 results: net income Net loss was $11.0 million for the nine months ended September 30, 2023.

Period: the quarter ended September 30, 2023
Net income: Net loss was $11.0 million for the nine months ended September 30, 2023
Result: reported results

Exact text from the filing

GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2023, and provided a business update.

View on SEC.gov

Browse all earnings releases →

GRI Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001824293-23-000172

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.